Login

OPIANT PHARMACEUTICALS, INC. SEC Filings

Filed On Filing
11 Jul 2023 CT ORDER
13 Mar 2023 15-12G
09 Mar 2023 EFFECT
09 Mar 2023 EFFECT
09 Mar 2023 EFFECT
06 Mar 2023 POS AM
06 Mar 2023 POS AM
06 Mar 2023 POS AM
06 Mar 2023 S-8 POS
06 Mar 2023 S-8 POS
06 Mar 2023 S-8 POS
06 Mar 2023 S-8 POS
06 Mar 2023 S-8 POS
06 Mar 2023 S-8 POS
03 Mar 2023 Form 4: Silver Gabrielle Alison, Director

Returned 23,343 shares to the issuer ($467K) · Disposed of 7,500 Stock Option (right to buy) (Disposition to Issuer) · Disposed of 2,500 Common Stock (Disposition to Issuer)

03 Mar 2023 Form 4: Collard Craig A, Director

Returned 55,822 shares to the issuer ($1.12M) · Disposed of 7,500 Common Stock (Disposition to Issuer) · Disposed of 5,000 Stock Option (right to buy) (Disposition to Issuer)

03 Mar 2023 Form 4: Ruth Matthew R., Chief Commercial Officer

Returned 31,916 shares to the issuer ($638K) · Received 2,000 shares as a grant or award · Disposed of 50,000 Stock Option (right to buy) (Disposition to Issuer)

03 Mar 2023 Form 4: Daly Richard J, Director

Returned 7,800 shares to the issuer ($156K) · Disposed of 10,000 Stock Option (right to buy) (Disposition to Issuer) · Disposed of 2,500 Common Stock (Disposition to Issuer)

03 Mar 2023 Form 4: Crystal Roger, Director

Returned 82,006 shares to the issuer ($1.64M) · Returned 5,100 shares to the issuer ($102K) · Received 6,667 shares as a grant or award · 3 more

03 Mar 2023 Form 4: Ellison Mark Jason Heath, Chief Development Officer

Returned 30,431 shares to the issuer ($609K) · Received 2,000 shares as a grant or award · Disposed of 15,450 Common Stock (Disposition to Issuer) · 1 more

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support